title: [Hormonal status and overexpression of HER2 in breast cancer, Cancerology department of Treichville UHC. Preliminary results].
abstract: OBJECTIVE
  
  
  
  OBJECTIVE
  determine the profile of the hormonal receptors and HER2 in order to optimize the patient's treatment by hormonotherapy and to propose targeted therapeutic to the few patients can procure themselves, when the indication is put.
  
  
  OBJECTIVE
  show the feasibility of these exams in sub-Saharan Africa and also the necessity to improve the technical tray permitting to do these exams in routine thus.
  
  
  METHODS
  Preliminary results of a prospective, descriptive study, on 10 months, achieved to the Cancerology service of Treichville CHU in Abidjan (Ivory Coast). Our results were about 22 patients.
  
  
  RESULTS
  The middle age of our patients was of 42.7 years. The stages to the diagnosis were advanced (86%) with nodes metastasis (77%), 8 patients out of 20 were RH+ of which only one postmenopausal patient, 8 patients out of 20 were HER2+ of which 2 to 2++ and 6 to 3+++. The FISH test has been achieved for the 2 positive patients to 2 ++ by IHC and came back positive. One of patients HER2+ could have adjuvant Herceptin.
  
  
  CONCLUSIONS
  Breast cancer is bad prognosis affection in our developing countries because of the patient's young age, of the advanced stages to the diagnosis. The knowledge of the status of the hormonal receptors and the HER2 over expression is necessary, as well the importance to pursue this survey and to set up an immunohistochemy unit in Ivory Coast. It will permit the realization in routine of these exams and, then, the improvement of the breast cancer patient's treatment.
authors.affiliation: Service de cancérologie, CHU de Treichville, BP V3 Abidjan, Côte-d'Ivoire. didi_coulibaly@yahoo.fr
authors.forename: J Didi-Kouko
authors.initials: JD
authors.lastname: Coulibaly
authors.forename: A B
authors.initials: AB
authors.lastname: Effi
authors.forename: G A
authors.initials: GA
authors.lastname: Horo
authors.forename: A
authors.initials: A
authors.lastname: Diabate
authors.forename: K
authors.initials: K
authors.lastname: Mbra
authors.forename: I
authors.initials: I
authors.lastname: Adoubi
authors.forename: M
authors.initials: M
authors.lastname: Toure
authors.forename: A
authors.initials: A
authors.lastname: Osseni
authors.forename: K A
authors.initials: KA
authors.lastname: Echimane
mesh_terms: D000328:Adult; D017954:Africa South of the Sahara; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000737:chemistry* / Q000188:drug therapy / Q000473:pathology; D007560:Cote d'Ivoire; D005240:Feasibility Studies; D005260:Female; D006801:Humans; D008207:Lymphatic Metastasis; D009367:Neoplasm Staging; D011446:Prospective Studies; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000032:analysis*; D011960:Receptors, Estrogen / Q000032:analysis*; D011980:Receptors, Progesterone / Q000032:analysis*; D000068878:Trastuzumab
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018931:Antineoplastic Agents, Hormonal; D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; D000068878:Trastuzumab